Amneal: Positive Topline Results in Parkinson's Phase 3 Trial

 Study was successful in demonstrating statistically significant improvement in efficacy for IPX-203 compared to immediate-release CD/LD, even when IPX-203 was dosed on average three times per day and immediate-release CD/LD was dosed on average five times per day

- New Drug Application submission to the FDA planned for mid-2022

- Company to host conference call to discuss trial results today at 4:30 p.m. ET

Conference Call Details
Amneal will host a conference call today, Wednesday, August 25, 2021, at 4:30 p.m. ET that will feature members of Amneal’s management team as well as Alberto Espay, MD, MSc, FAAN, FANA (University of Cincinnati), and Robert A Hauser, MD, MBA, FAAN (University of South Florida) to discuss topline results from the pivotal Phase 3 RISE-PD clinical trial. The presentation will be followed by a live Q&A session.

Please visit https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp?Y2lk=MTM2Mg== to register and access the live webinar. A replay will be made available on the company’s website for six months. The presentation materials will be posted on the Investor Relations website following the conclusion of the event.

https://finance.yahoo.com/news/amneal-announces-positive-topline-results-200100858.html